For example, intravenous recombinant tissue plasminogen activator (R-TPA) is currently approved for the clinical treatment of ischemic stroke [3]; however, most patients do not have access to thrombolytic therapy because of the three-hour treatment window. Here, PLAT is linked to ischemic stroke.